The Journal of Allergy and Clinical Immunology: In Practice

Slides:

Advertisements

Similar presentations

Biologics in Asthma—The Next Step Toward Personalized Treatment

Advertisements

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

David B. Price, FRCGP, Miguel Román-Rodríguez, MD, R

Pinja Ilmarinen, PhD, Leena E

Complementary and Alternative Medicine Use among Allergy Practices: Results of a Nationwide Survey of Allergists Michael H. Land, MD, Julie Wang, MD

The Relationship Between a Specific IgE Level and Asthma Outcomes: Results from the National Health and Nutrition Examination Survey Whitney.

Once-daily tiotropium add-on to at least ICS improves control and reduces exacerbation risk in symptomatic asthma, independent of serum IgE or blood.

Asthma Yardstick Annals of Allergy, Asthma & Immunology

Mental Health Services Claims and Adult Onset Asthma in Ontario, Canada Teresa To, PhD, Kandace Ryckman, MPH, Jingqin Zhu, MSc, Devon Williams, MSc, Laura.

Diagnostic Accuracy of Inflammatory Markers for Diagnosing Occupational Asthma Geneviève Racine, Roberto Castano, MD, PhD, André Cartier, MD, Catherine.

Advances in Diagnosing Peanut Allergy

Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study Eli O. Meltzer, MD, Paul.

The Role of the Primary Care Physician in Helping Adolescent and Adult Patients Improve Asthma Control Barbara P. Yawn, MD, MSc Mayo Clinic Proceedings

Asthma Phenotypes Defined From Parameters Obtained During Recovery From a Hospital-Treated Exacerbation Rihuang Qiu, MD, Jiaxing Xie, MD, PhD, Kian Fan.

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.

The Natural History of Food Allergy

Long-Term Inhaled Corticosteroid Adherence in Asthma Patients with Short-Term Adherence Laurent Laforest, MD, PhD, Manon Belhassen, MSc, Gilles Devouassoux,

Complementary and Alternative Medicine in Allergy-Immunology: More Information is Needed Leonard Bielory, MD The Journal of Allergy and Clinical Immunology:

Wells Syndrome with Bullous Lesions

Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial Huib A.M. Kerstjens, MD, PhD, Bernd Disse,

Dennis K. Ledford, MD, Sally Wenzel, MD

A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma Stanley J. Szefler, MD, Kevin Murphy,

Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma Christian Vogelberg, MD, PhD, Michael Engel, MD, István.

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial Pierluigi Paggiaro,

Desensitization to Chemotherapeutic Agents

Volume 151, Issue 2, Pages (February 2017)

Badrul A. Chowdhury, MD, PhD

An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

Michael Schatz, MD, MS, Robert S

Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life Bradley E. Chipps, MD, Tmirah Haselkorn, PhD, Karin Rosén, MD, PhD,

Evaluation of Food Allergy in Patients with Atopic Dermatitis

The Relationship Between a Specific IgE Level and Asthma Outcomes: Results from the National Health and Nutrition Examination Survey Whitney.

Advances in Diagnosing Peanut Allergy

A) Peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) response following once-daily tiotropium Respimat add-on to medium-dose.

Nonadherence to Asthma Treatment: Getting Unstuck

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study Thomas B. Casale, MD, Allan.

Peter M. Wolfgram, MD, David B. Allen, MD

Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients.

Aimee L. Speck, MD, Michael Hess, MSI, Alan P. Baptist, MD, MPH

Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma Hector Ortega, MD, ScD, Steven W. Yancey, MS,

Penicillin Skin Testing Is a Safe and Effective Tool for Evaluating Penicillin Allergy in the Pediatric Population Stephanie J. Fox, MD, Miguel A. Park,

Paul M. O’Byrne, MB, FRCPI, FRCP(C)a, Soren Pedersen, MD, PhDb

Body mass index, weight gain, and other determinants of lung function decline in adult asthma Alessandro Marcon, MSc, Angelo Corsico, MD, PhD, Lucia.

Change in Asthma Control Over Time: Predictors and Outcomes

Phillip Lieberman, MD, Michael Tankersley, MD

Pinja Ilmarinen, PhD, Leena E

Thomas B. Casale, MD, Tmirah Haselkorn, PhD, Christina E

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

The Management of Eosinophilic Esophagitis

Phillip Lieberman, MD, David Golden, MD

Michael Schatz, MD, MS, Robert S

Sinonasal Papillomas and Natural Killer–Cell Deficiency

Pinja Ilmarinen, PhD, Leena E

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

Sharon Seth, MD, David A. Khan, MD

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

Cephalosporin Side Chain Cross-reactivity

Clinical need for a nebulized corticosteroid

Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma Hector Ortega, MD, ScD, Steven W. Yancey, MS,

Granulomatous-lymphocytic Interstitial Lung Disease in a Patient with Common Variable Immunodeficiency Phil Lieberman, MD, John Routes, MD The Journal.

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to previous chronic obstructive pulmonary.

Administration of Intravenous Immunoglobulin to a Patient with Hypogammaglobulinemia and Anti-IgA Antibodies Phillip Lieberman, MD, Rima Rachid, MD

Amy Hai Yan Chan, BPharm(Hons), Jeff Harrison, PhD, Peter N

Reply The Journal of Allergy and Clinical Immunology: In Practice

Eckard Hamelmann, MD, Eric D

Larry C. Borish, MDa, Harold S

Adjusted mean±se response in peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) at week 24, following once-daily tiotropium Respimat.

Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies Frank C. Albers, MD, PhD, Robert G. Price,

Presentation transcript:

The Journal of Allergy and Clinical Immunology: In Practice Tiotropium reduces airflow obstruction in asthma patients, independent of body mass index Sandhya Khurana, MD, Pierluigi Paggiaro, MD, Roland Buhl, MD, Jonathan A. Bernstein, MD, FACP, CCI, Jennifer Haddon, MSc, Anna Unseld, Dipl. Stat, Michael Engel, MD, Thomas B. Casale, MD, Anne E. Dixon, MD The Journal of Allergy and Clinical Immunology: In Practice DOI: 10.1016/j.jaip.2019.03.007 Copyright © 2019 The Authors Terms and Conditions

Figure 1 Study design for (A) PrimoTinA-asthma (B) MezzoTinA-asthma, and (C) GraziaTinA-asthma. HFA-MDI, Hydrofluoroalkane metered-dose inhaler; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist. The trials included adult patients aged 18 to 75 years. Patients in the 2 PrimoTinA-asthma trials had symptomatic severe asthma, patients in the 2 MezzoTinA-asthma trials had symptomatic moderate asthma, and patients in the GraziaTinA-asthma trial had symptomatic mild asthma. The Journal of Allergy and Clinical Immunology: In Practice DOI: (10.1016/j.jaip.2019.03.007) Copyright © 2019 The Authors Terms and Conditions

Figure E1 FEV1(0-3h) peak and FEV1 trough adjusted placebo-corrected mean change from baseline. A, Tiotropium 5 μg FEV1(0-3h) peak levels. B, Tiotropium 5 μg FEV1 trough levels. C, Tiotropium 2.5 μg FEV1(0-3h) peak levels. D, Tiotropium 2.5 μg FEV1 trough levels. BMI, Body mass index; FEV1, forced expiratory volume in 1 second; FEV1(0-3h), forced expiratory volume in 1 second 3 hours postdose. The Journal of Allergy and Clinical Immunology: In Practice DOI: (10.1016/j.jaip.2019.03.007) Copyright © 2019 The Authors Terms and Conditions

Figure E2 FEV1(0-3h) peak adjusted mean change from baseline vs placebo across the continuous range of BMI values for (A) tiotropium 5 μg vs placebo and (B) tiotropium 2.5 μg vs placebo. BMI, Body mass index; CI, confidence interval; FEV1, forced expiratory volume in 1 second; FEV1(0-3h), forced expiratory volume in 1 second 3 hours postdose; Tio, tiotropium. The Journal of Allergy and Clinical Immunology: In Practice DOI: (10.1016/j.jaip.2019.03.007) Copyright © 2019 The Authors Terms and Conditions

Figure E3 FEV1 trough adjusted mean change from baseline vs placebo across the continuous range of BMI values for (A) tiotropium 5 μg vs placebo and (B) tiotropium 2.5 μg vs placebo. BMI, Body mass index; CI, confidence interval; FEV1, forced expiratory volume in 1 second; Tio, tiotropium. The Journal of Allergy and Clinical Immunology: In Practice DOI: (10.1016/j.jaip.2019.03.007) Copyright © 2019 The Authors Terms and Conditions